Kornimate/medical-research-clean huggingface dataset:
cast or functional ankle orthosis after ankle fracture surgery

Conditions: Ankle Fracture; Postoperative Treatment

Summary: the goal of this randomized clinical trial was to compare the effect of 6-week casting versus 2-week casting followed by 4-week ankle bracing in adult patients with surgically treated ankle fractures. the primary outcome measures used were the functional results 3 months after surgery evaluated using two functional outcome measures (olerud and molander score and kaikkonen score) and the patient return to work. in the casting group, the traditional plaster was changed to a fiberglass one at 2 weeks and the cast treatment continued until 6 weeks. in the functional treatment group, the traditional plaster cast was changed to an reusable semi-rigid plastic orthosis (aircast) at 2 weeks after surgery and its use was continued as an ankle support for up to 6 weeks. follow-ups including subjective and objective evaluations were at 2, 6, 12 and 52 weeks and at 2 years postoperatively.


Eligibility criteria:
inclusion criteria: * weber a or b type ankle fracture * uni-, bi- or trimalleolar injury and/or fibular displacement of \>2 mm in any plane on the radiographs exclusion criteria: * weber c injury necessitating syndesmotic fixation * pilon injury * inadequate co-operation * other severe concomitant injuries
neuromuscular electrical stimulation via the peroneal nerve reduces muscle soreness following intermittent exercise

Conditions: Delayed Onset Muscle Soreness

Summary: numerous techniques are reported to enhance recovery following intense exercise, however there is equivocal support for such claims. a novel technique of neuromuscular electrical stimulation (nmes) via the peroneal nerve has been shown to augment limb blood flow which could enhance recovery following exercise. the present study examined the effects of nmes, compared to graduated compression socks on muscle soreness, strength, and markers of muscle damage and inflammation following intense intermittent exercise.


Eligibility criteria:
inclusion criteria: * healthy males * currently playing intermittent sports (such as soccer, field hockey, rugby) * currently representing their respective sports at either university, county, national or international levels exclusion criteria: * unhealthy males * not currently playing intermittent sports (such as soccer, field hockey, rugby) * not currently representing their respective sports at either university, county, national or international levels * individuals indicating a history of cardiovascular, metabolic or haematological disorders * participants reporting a sedentary lifestyle of less than three 30-min physical activity sessions per week

Keywords: delayed onset muscle soreness muscle damage muscle function inflammation
transcranial direct current stimulation (tdcs) as an adjunctive treatment for treatment resistant depression (trd)

Conditions: Treatment Resistant Depression

Summary: the researchers are trying to test the feasibility and acceptability of using transcranial direct current stimulation (tdcs) in hospitalized adult patients with treatment resistant depression (trd), assess for any preliminary effect on depressive and cognitive symptoms, and explore the utility of biomarkers to assess response to tdcs.

in this feasibility study the researchers propose to conduct a 5-day tdcs treatment protocol in hospitalized adult patients with trd, with each treatment session lasting for 30 minutes, delivered twice daily, for a total of 10 stimulations over 5 days. before and after the 5-day tdcs treatment protocol, assessments will include montgomery-asberg depression rating scale (madrs) to measure depressive symptoms, snaith-hamilton pleasure scale (shaps) to measure anhedonia, stroop test to measure memory and executive function, revised hopkins verbal learning test (hvlt-r) to test verbal learning and memory, and digital symbol coding test (dsct) to measure working memory. electroencephalography (eeg) for objective electrophysiologic data will also be collected before and after tdcs. a wireless eeg unit (cgx, cognionic, inc.) will be used to collect eeg and peak alpha frequency (paf) as potential target engagement marker for tdcs. the paf measures the highest magnitude within the alpha range of brain oscillations, thought to reflect cognitive performance. other potential predictors of treatment response measures collected at baseline include adverse childhood experiences (ace), premorbid intelligence quotient (piq), wide range achievement reading test (wrart), and socioeconomic status (ses).

Eligibility criteria:
inclusion criteria * 18 years and older * clinical diagnosis of treatment-resistant depression (defined as depression that does not remit following two or more treatment attempts of an adequate dose and duration of a minimum duration of 4 weeks) * hospitalized in psychiatric units * voluntary admission status * moderate or severe depression, defined by phq-9 ≥ 15 * ability to provide informed consent * ability to adhere to protocol exclusion criteria * bipolar disorder * active primary psychotic or substance use disorders (except nicotine dependence) within the past year * any active neurological condition (including seizure disorder, traumatic brain injury, stroke) * contraindications to tdcs (including pacemaker, metallic implants in the head or neck \[except orthodontic hardware\], skin disease causing irritation) * current pregnancy or positive urine pregnancy test (clinical) * any neuromodulation therapy (including ect, rtms, dbs, vns, tes) within the last 3 months
tissue sample collection from patients with soft tissue sarcoma of the arms, hands, legs, or feet treated on clinial trial cruk-vortex

Conditions: Sarcoma

Summary: rationale: collecting and storing samples of tumor tissue from patients with soft tissue sarcoma to test in the laboratory may help the study of cancer in the future. purpose: this laboratory is collecting tissue samples from patients with soft tissue sarcoma of the arms, hands, legs, or feet treated on clinical trial cruk-vortex.

objectives: * determine early in the course of treatment which patients treated on clinical trial cruk-vortex have an increased likelihood of distant metastases so as to highlight individuals who might benefit from early adjuvant systemic therapy. outline: this is a multicenter study. tumour and normal tissue samples will be taken at the time of surgery during treatment on clinical trial cruk-vortexand preserved for future microarray analyses. tissue microarrays will be produced from both tumor and normal tissues. blood samples will be collected for future dna analysis.

Eligibility criteria:
disease characteristics: * histologically confirmed soft tissue sarcoma * receiving treatment on clinical trial cruk-vortex * underwent surgery to remove the tumor no more than 3 months ago patient characteristics: * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception during and for 3 months after completion of study treatment * no other major medical illness that would preclude study treatment * no other prior or concurrent malignancy except adequately treated nonmelanoma carcinoma of the skin or in situ carcinoma of the cervix prior concurrent therapy: * no prior radiotherapy to the local site * no prior neoadjuvant or adjuvant chemotherapy

Keywords: recurrent adult soft tissue sarcoma stage i adult soft tissue sarcoma stage ii adult soft tissue sarcoma stage iii adult soft tissue sarcoma adult synovial sarcoma adult angiosarcoma adult epithelioid sarcoma adult extraskeletal chondrosarcoma adult leiomyosarcoma adult liposarcoma adult malignant fibrous histiocytoma adult malignant hemangiopericytoma adult malignant mesenchymoma adult fibrosarcoma adult neurofibrosarcoma
combined application of ebus and eus in lung cancer

Conditions: Non Small Cell Lung Cancer

Summary: this study aims to investigate a diagnostic yield and performance characteristics according to the order of endobronchial ultrasound guided transbronchial needle aspiration (ebus-tbna) and endoscopic ultrasound-with bronchoscope-guided transbronchial needle aspiration (eus-b-fna) in the mediastinal staging of potentially operable lung cancer. eus-fna is a better tolerated procedure than ebus-tbna. therefore, eus-b-fna can be the main procedure in a combined approach with ebus-tbna and eus-b-fna. in group a, the investigators perform ebus-tbna first and eus-b-fna is performed when necessary. in group b, eus-b-fna is first applied and ebus-tbna is performed when necessary. the hypothesis is that the diagnostic yield of the eus centered procedure is as good as that of the ebus centered procedure and the eus centered procedure is more tolerable than the ebus centered procedure. we evaluate diagnostic yields and performance characteristics of each group.


Eligibility criteria:
inclusion criteria: * histologically confirmed or strongly suspected non-small cell lung cancer (nsclc) * potentially operable patients exclusion criteria: * m1 disease * inoperable t4 disease * mediastinal infiltration or extranodal invasion of the mediastinal lymph node visible on chest ct. * confirmed supraclavicular lymph node metastasis * pancoast tumors * medically inoperable patients * contraindications for bronchoscopy and esophageal endoscopy * drug reaction to lidocaine, midazolam,fentanyl * pregnancy * ground glass-dominant nodule ( \< 3cm)

Keywords: endobronchial ultrasound endoscopic ultrasound ebus-tbna eus-fna eus-b-fna lung cancer staging
a trial to study the influence of growth factors on bone marrow and hepatic regeneration in patients with decompensated cirrhosis.

Conditions: Decompensated Cirrhosis

Summary: this will be a randomized double blind study which will be conducted on patients admitted to department of hepatology from june 2013 to may 2014 at ilbs, new delhi. patients not having any exclusion criteria will undergo bone marrow examination and liver biopsy at the baseline. 60 patients of decompensated cirrhosis will be randomised into two limbs- limb a (30 patients) will receive g-csf and erythropoietin while those on limb b (30 patients) will receive g-csf alone. the drugs will be given for 2 months and patient will be followed for 1 year. g-csf will be given at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 60 (total 22 doses). erythropoietin will be given s/c at dose of 500 iu/kg twice a week for 2 months. follow up will be done on days 0,3,7,14,28, day 42 (6 weeks), day 60 (2 months), day 90 (3 months), day 180 (6 months), day 270 (9 months); and day 360 (1 year).


Eligibility criteria:
inclusion criteria: * subjects aged 18-65 years * all patients who are known to have cirrhosis of liver with portal hypertension and are compensated on presentation with no features of ascites/ jaundice/ bleed/ he/ hrs. * only patients with alcoholic cirrhosis and cryptogenic cirrhosis (etiology work up negative) will be enrolled in the study. exclusion criteria: * sepsis ( any culture positive: blood, urine, any other obvious source of infection: uti, lrti) * variceal bleed in the past 3 months * autoimmune disorders * hcc (hepatocellular carcinoma) * multi organ failure * any features of decompensation in form of ascites/jaundice/ he (grade 3 or 4) / hrs * hiv seropositivity * essential hypertension * pregnancy * refusal to participate in the study
acoustic liver biopsy in normals and in patients with cirrhosis using endoscopic ultrasound

Conditions: Alcoholism; Cirrhosis; Hepatitis c

Summary: the purpose of this study is to determine the amount of fibrosis in the liver of hepatitis c patients with advanced fibrosis, using endoscopic ultrasound.

background: transabdominal ultrasound cannot be used to quantitate fibrosis in patients with cirrhosis due to variability in the abdominal wall thickness and composition. this variability can be eliminated by using endoscopic ultrasound. aim: to determine the amount of fibrosis in the liver of hepatitis c patients with advanced fibrosis, using endoscopic ultrasound.

Eligibility criteria:
inclusion criteria: * hepatic cirrhosis and hepatitis c and undergoing endoscopy * alcoholic liver and undergoing endoscopy * normal liver undergoing endoscopy exclusion criteria: * pregnancy * children

Keywords: alcoholic cirrhosis hepatitis c cirrhosis cirrhosis
open versus endoscopic surgery of craniomaxillofacial (cmf) condylar neck fractures

Conditions: Condylar Neck Fractures

Summary: this study is a comparison of open surgery versus an endoscopic approach in condylar neck fractures; it will look at functional outcome, cosmetic outcome and patient satisfaction.

the primary outcome measure is functional outcome based on the helkimo dysfunction index.

Eligibility criteria:
inclusion criteria: * adult patient \> 18 years * unilateral or bilateral fracture of the condylar neck * inclination of the condyle \> 30% * severe dislocation * severe pain upon palpation/movement * eligible for open reduction and internal fixation of the fracture * amenable to endoscopic as well as open surgery exclusion criteria: * high or intracapsular condylar neck fracture * very low fractures that can be reduced intraorally * cmf malfunctioning * drug or alcohol abuse * general or local conditions that adversely affect bone physiology * physical or mental incapacity to sign informed consent

Keywords: condylar neck fractures endoscopic helkimo dysfunction index
effectiveness of a combined dermatological treatment in children with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to determine the effectiveness of a combined dermatological treatment in children up to 5 years old with mild or moderated atopic dermatitis.

the intensive cream and body lotion of the pediatopic® products are two emollients expressly formulated to serve as adjuvants in the management of atopic dermatitis. both products contain dermosense complex®, a complex that includes 3 products: bodyfensine peptide® (inductor of dephensine synthesis against microbial aggressions), unimoist® (the mimetizing complex of the skin's natural hydration factor), and ramnosoft® (polysaccharide that inhibits the adhesion of pro-inflammatory drugs and bacteria, while limiting the spread of inflammatory reactions in skin cells). they also contain bisabolol, (plant extract with anti-inflammatory, anti-irritant and antimicrobial properties) and panthenol (pro vitamin b5 that accelerates the skin's natural regeneration process).

Eligibility criteria:
inclusion criteria: * children from 1 month to 5 years old * patients with atopic dermatitis mild-moderate with an scorad=16-40 exclusion criteria: * other dermatological diseases that could interfere with the study results * corticoids use during 3 weeks prior to the study * antibiotics use to treat atopic dermatitis during 3 weeks prior to the study * use of topical immunomodulators * concurrent use of other emollients
changes of soft tissue grafting: a randomized study

Conditions: Gingival Recession

Summary: to correct gum recession, patient's own tissue from the roof of the mouth is harvested and placed where there is root exposed. this is considered gold standard of treatment. sometimes patient don't want to have second surgical site in their mouth and at the same time do not want to use alternative tissue from human or animal donor. using patients' blood and preparing it as a membrane is the next best thing to correct gum recession.

patients that are interested in having corrective surgery for recession due to esthetic concerns or sensitivity will be enrolled in the study. the treatment site will randomly receive the procedure assignment. intraoral scanner will be utilized to establish pre-op volume and will be repeated at each follow up visit. total of 12 visits and 5 year duration is anticipated for the study.

Eligibility criteria:
inclusion criteria: 1. adults 18yrs or older 2. need of mg-tx for 2 or more sites for root coverage rt i and ii (cairo classification) 3. class a +/- 4. no class v restoration present exclusion criteria: 1. patients who do not consent to recommended therapy 2. patients who smoke 3. patients who will not be able to comply with follow up protocols 4. those who self report that they are pregnant.
real-world study of utd1 in chinese advanced breast cancer

Conditions: Breast Cancer

Summary: to evaluate the efficacy and safety of utd1 in patients with advanced breast cancer.


Eligibility criteria:
inclusion criteria: 1. patients aged over 18 years old. 2. metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage iv breast cancer, and recurrent metastatic breast cancer. 3. plan to receive or has received utd1 monotherapy or utd1 based therapy 4. available medical history. exclusion criteria: 1.incomplete medical history.
prevalence and characteristics of nonpolypoid colorectal neoplasms - a chinese cohort study

Conditions: Nonpolypoid Colorectal Neoplasms(NP-CRN)

Summary: the nonpolypoid colorectal neoplasms (np-crns) are relatively common in patients with gastrointestinal alarm systoms. the depressed lesions have a greater risk of having cancer than flat and polypoid lesions.


Eligibility criteria:
inclusion criteria: * consecutive adult patients undergo colonoscopy by one endoscopist

Keywords: nonpolypoid colorectal neoplasms(np-crn) prevalence histology
adjuvant chemotherapy with or without intercalated icotinib

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: epidermal growth factor receptor (egfr) mutations occur in up to 50% of asian patients with non-small cell lung cancer (nsclc). treatment of advanced nsclc patients with egfr-tyrosine kinase inhibitors (egfr-tki) confers a significant survival benefit. this study aims to assess the efficacy and safety of adjuvant chemotherapy with or without intercalated combination of icotinib in patients undergoing resection of stage iib to iiia (n1-2) egfr-mutated nsclc.


Eligibility criteria:
inclusion criteria: * patients undergoing completely resection of egrf mutation-positive nsclc staging iib to ⅲa, n1-2; ps = 0 or 1; adequate hematological, biochemical and organ functions exclusion criteria: * systemic anticancer therapy prior to surgery, other malignancies before or during the study, any unstable illness, women who were pregnant or lactating
bioequivalence study of pimecrolimus cream, 1% and elidel® cream, 1% in mild to moderate atopic dermatitis

Conditions: Atopic Dermatitis

Summary: to establish the bioequivalence between test drug, pimecrolimus cream, 1% with that of reference listed drug, elidel® (pimecrolimus) cream 1%, in the treatment of mild to moderate atopic dermatitis. to establish superiority of each active treatment over the placebo.


Eligibility criteria:
inclusion criteria: * non-immuno compromised male or female aged 8 years and older * clinical diagnosis of mild to moderate atopic dermatitis (ad) * failed to respond adequately to other topical prescription treatments for ad, or for whom those treatments are not advisable. * a diagnosis of ad for at least 3 months * an investigator's global assessment (iga) of disease severity of mild or moderate at baseline (score of 2 or 3) * affected area of ad involvement at least 5% body surface area (bsa) * treated with a bland emollient for at least 7 days exclusion criteria: * females who are pregnant, breast feeding, or who wish to become pregnant during the study period * active cutaneous bacterial or viral infection in any treatment area at baseline (e.g., clinically infected atopic dermatitis, impetigo). * sunburn, extensive scarring or pigmented lesion(s) in any treatment area at baseline, which would interfere with evaluations * history or presence of confounding skin conditions, e.g., psoriasis, rosacea, erythroderma, ichthyosis, or scabies. * history or presence of netherton's syndrome, immunological deficiencies or diseases, hiv, diabetes, malignancy, serious active or recurrent infection, clinically significant severe renal insufficiency or severe hepatic disorders * concurrent disease or treatment likely to interfere with the study treatment or evaluations * known allergy or hypersensitivity to pimecrolimus or any other component of the drug products * not willing to minimize or avoid natural and artificial sunlight exposure during treatment
changes of clinical characteristics and tear film biomarkers following fs-lasik

Conditions: Dry Eye

Summary: to analyze the clinical and tear molecular profile up to 6 months after fs-lasik surgery

fs-lasik is a refractive surgery technique widely used in china. to explore the role of inflammation and nerve in the occurrence and development of dry eyes after fs-lasik by dynamically observing the ocular surface characteristics and the levels of inflammatory factors and neurotransmitters in the early and late stage after fs-lasik.

Eligibility criteria:
inclusion criteria: 1. patients who preparing for fs-lasik with age between 18 and 45 years old 2. any gender 3. provision of written informed consent. exclusion criteria: 1. active ocular infection, ocular inflammation, active ocular allergy, severe blepharitis or obvious inflammation of the eyelid margin. 2. pregnant and lactating women, or those planning a pregnancy over the course of the study 3. uncontrolled systemic disease 4. suffer from diseases that may affect corneal nerves, such as keratoconus, trigeminal neuralgia, allergic conjunctivitis, etc.
biomarkers of resiliency in childhood cancer surgery

Conditions: Pediatric Cancer; Neuroblastoma; Sarcoma; Wilms Tumor and Other Childhood Kidney Tumors; Childhood Soft Tissue Sarcoma

Summary: this observational study is to better understand how children and their families recover after the stress of major surgery for cancer so that investigators can create ways to improve resilience during recovery. the main questions it aims to answer are: 1. can information obtained from patients and their caregivers wearing smartwatches and answering questionnaires be used to measure how patients are recovering from surgery? 2. are there specific patterns in patients' circulating proteins and metabolites that are associated with stress after surgery? participants, including pediatric patients undergoing surgery for cancer and their primary caregiver, will be asked to: * wear a smartwatch * complete questionnaires * allow for extra blood to be drawn for this research study when they are having their regular blood draws for clinical purposes these actions will occur at baseline prior to patients' surgery and then afterwards for up to one year. there are no changes to participants' clinical care or surgical care as a result of the study. investigators will also collect participants' clinical information and cancer-specific outcomes. participants will be remunerated for their time.


Eligibility criteria:
inclusion criteria: * 3-18 years old at enrollment * with solid tumors of the chest, abdomen, and extremities including neuroblastic tumors, sarcoma including soft tissue and bone, kidney tumors, liver tumors, ovarian tumors, lung and pleural-based tumors, and intestinal tumors -or- * guardian or primary caregiver of patient 3-18 years old with one of the aforementioned tumors. exclusion criteria: * patients who are known to be pregnant or prisoners.

Keywords: digital biomarker remote monitoring smartwatch surgery pediatric cancer